252 related articles for article (PubMed ID: 33335078)
1. Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer.
Menendez JA; Peirce SK; Papadimitropoulou A; Cuyàs E; Steen TV; Verdura S; Vellon L; Chen WY; Lupu R
Aging (Albany NY); 2020 Dec; 12(24):24671-24692. PubMed ID: 33335078
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
3. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.
Corominas-Faja B; Vellon L; Cuyàs E; Buxó M; Martin-Castillo B; Serra D; García J; Lupu R; Menendez JA
Histol Histopathol; 2017 Jul; 32(7):687-698. PubMed ID: 27714708
[TBL] [Abstract][Full Text] [Related]
4. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
Leehy KA; Truong TH; Mauro LJ; Lange CA
J Steroid Biochem Mol Biol; 2018 Feb; 176():88-93. PubMed ID: 28442393
[TBL] [Abstract][Full Text] [Related]
6. Fatty Acid Synthase Is a Key Enabler for Endocrine Resistance in Heregulin-Overexpressing Luminal B-Like Breast Cancer.
Menendez JA; Mehmi I; Papadimitropoulou A; Vander Steen T; Cuyàs E; Verdura S; Espinoza I; Vellon L; Atlas E; Lupu R
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081219
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
8. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
9. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
11. Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression.
Ferraris J; Boutillon F; Bernadet M; Seilicovich A; Goffin V; Pisera D
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E356-64. PubMed ID: 22094470
[TBL] [Abstract][Full Text] [Related]
12. Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib.
Li CF; Fang FM; Chen YY; Liu TT; Chan TC; Yu SC; Chen LT; Huang HY
Clin Cancer Res; 2017 Aug; 23(16):4908-4918. PubMed ID: 28442505
[No Abstract] [Full Text] [Related]
13. ck2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells.
Hagan CR; Regan TM; Dressing GE; Lange CA
Mol Cell Biol; 2011 Jun; 31(12):2439-52. PubMed ID: 21518957
[TBL] [Abstract][Full Text] [Related]
14. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.
Ginsburg E; Alexander S; Lieber S; Tarplin S; Jenkins L; Pang L; Heger CD; Goldsmith P; Vonderhaar BK
BMC Cancer; 2010 Dec; 10():678. PubMed ID: 21144038
[TBL] [Abstract][Full Text] [Related]
15. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Jacobsen BM; Schittone SA; Richer JK; Horwitz KB
Mol Endocrinol; 2005 Mar; 19(3):574-87. PubMed ID: 15563544
[TBL] [Abstract][Full Text] [Related]
16. Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population.
Recouvreux MS; Diaz Bessone MI; Taruselli A; Todaro L; Lago Huvelle MA; Sampayo RG; Bissell MJ; Simian M
Cells; 2020 Sep; 9(9):. PubMed ID: 32932770
[TBL] [Abstract][Full Text] [Related]
17. Immunofluorescent localization of a novel progesterone receptor(s) in a T47D-Y breast cancer cell line lacking genomic progesterone receptor expression.
Price TM; Hansen EL; Oliver TN
J Soc Gynecol Investig; 2005 Dec; 12(8):610-6. PubMed ID: 16325750
[TBL] [Abstract][Full Text] [Related]
18. Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells.
Wei LL; Krett NL; Francis MD; Gordon DF; Wood WM; O'Malley BW; Horwitz KB
Mol Endocrinol; 1988 Jan; 2(1):62-72. PubMed ID: 3398843
[TBL] [Abstract][Full Text] [Related]
19. Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.
Lim JT; Joe AK; Suzui M; Shimizu M; Masuda M; Weinstein IB
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3478-84. PubMed ID: 16740773
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal fine-tuning of progesterone and prolactin-regulated gene expression in breast cancer cells.
Holloran SM; Nosirov B; Walter KR; Trinca GM; Lai Z; Jin VX; Hagan CR
Mol Cell Endocrinol; 2020 Jul; 511():110859. PubMed ID: 32407979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
